Snus use and rejection in the USA
- PMID: 24570100
- PMCID: PMC4519419
- DOI: 10.1136/tobaccocontrol-2013-051342
Snus use and rejection in the USA
Abstract
Objective: To determine whether snus might become a strategy for reducing the harm associated with cigarette smoking in the USA as appears to be the case in Sweden, we examined receptivity to snus use in two cities with the greatest exposure to the major brands.
Methods: A dual frame, telephone survey and a brief mail survey were conducted in 2011 and 2012 in Indianapolis, Indiana and Dallas/Fort Worth Texas. Over 5000 adults completed surveys. Trial, ever use, current use and reasons for using or quitting snus after trial were measured.
Results: Among male smokers, 29.9% had ever tried snus (CI 22.7 to 38.1) and 4.2% were current users (CI 1.6 to 10.7). Among female smokers, 8.5% ever tried snus (CI 4.4 to 15.7) and current use was unknown. Current use was virtually absent among former smokers and never smokers. A major predictor of any level of snus use was current use of conventional smokeless tobacco. Those who tried and gave up snus cited curiosity (41.3%) and the fact that it was available at low or no cost (30%) as reasons for trial; reasons for not continuing included preferring another form of tobacco (75.1%) and disliking the mouth feel (34.6%). Almost all current snus users indicated that they were trying to cut down on cigarettes, but few (3.9%) were using it to quit smoking entirely.
Conclusions: The low rate of adoption of snus suggests that neither the hopes nor the fears surrounding this new product are likely to be realised in the USA with the current marketing patterns.
Keywords: Harm Reduction; Non-cigarette tobacco products; Public policy.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Conflict of interest statement
Dorothy Hatsukami received funding from Nabi Pharmaceuticals to be site for nicotine immunotherapy trial.
Similar articles
-
Do never smokers make up an increasing share of snus users as cigarette smoking declines? Changes in smoking status among male snus users in Norway 2003-15.Addiction. 2017 Feb;112(2):340-348. doi: 10.1111/add.13638. Epub 2016 Dec 5. Addiction. 2017. PMID: 27741374 Free PMC article.
-
Association between use of flavoured tobacco products and quit behaviours: findings from a cross-sectional survey of US adult tobacco users.Tob Control. 2016 Nov;25(Suppl 2):ii73-ii80. doi: 10.1136/tobaccocontrol-2016-053313. Epub 2016 Oct 5. Tob Control. 2016. PMID: 27708123 Free PMC article.
-
Associations of Proposed Relative-Risk Warning Labels for Snus With Perceptions and Behavioral Intentions Among Tobacco Users and Nonusers.Nicotine Tob Res. 2016 May;18(5):809-16. doi: 10.1093/ntr/ntv168. Epub 2015 Aug 7. Nicotine Tob Res. 2016. PMID: 26253616 Free PMC article.
-
Snus: a compelling harm reduction alternative to cigarettes.Harm Reduct J. 2019 Nov 27;16(1):62. doi: 10.1186/s12954-019-0335-1. Harm Reduct J. 2019. PMID: 31775744 Free PMC article. Review.
-
[Harm reduction strategy in tobacco control].Epidemiol Prev. 2011 May-Aug;35(3-4 Suppl 1):19-32. Epidemiol Prev. 2011. PMID: 21926451 Review. Italian.
Cited by
-
Establishing the Association Between Snus Use and Mental Health Problems: A Study of Norwegian College and University Students.Nicotine Tob Res. 2023 Jan 1;25(1):135-142. doi: 10.1093/ntr/ntac208. Nicotine Tob Res. 2023. PMID: 36037069 Free PMC article.
-
Intention to purchase alternative tobacco products as a function of smoking status and responses to advertising, packaging, and sensory experiences.Addict Behav. 2022 Jul;130:107291. doi: 10.1016/j.addbeh.2022.107291. Epub 2022 Feb 22. Addict Behav. 2022. PMID: 35220153 Free PMC article.
-
Acute effects of snus in never-tobacco users: a pilot study.Am J Drug Alcohol Abuse. 2018;44(1):113-119. doi: 10.1080/00952990.2016.1260581. Epub 2016 Dec 8. Am J Drug Alcohol Abuse. 2018. PMID: 27929684 Free PMC article. Clinical Trial.
-
Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching.Tob Control. 2016 May;25(3):267-74. doi: 10.1136/tobaccocontrol-2014-052080. Epub 2015 May 19. Tob Control. 2016. PMID: 25991608 Free PMC article. Clinical Trial.
-
Evaluation of modified risk claim advertising formats for Camel Snus.Health Educ J. 2017 Dec;76(8):971-985. doi: 10.1177/0017896917729723. Epub 2017 Sep 20. Health Educ J. 2017. PMID: 38974785 Free PMC article.
References
-
- Staff. Winston-Salem Journal. Winston-Salem; 2010. Altria Group to go national with smokeless Marlboro Snus.
-
- Craver R. Winston-Salem Journal. Winston-Salem; 2008. Reynolds is taking its snus national.
-
- Staff. Winston-Salem Journal. Winston-Salem; 2011. Lorillard CEO: No need to venture beyond cigs.
-
- Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiology Biomarkers Prev. 2004;13:2035–2042. - PubMed
-
- Luo J, Ye W, Zendehdel K, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A restrospective cohort study. Lancet. 2007;369:2015–2020. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical